Replies to post #182650 on Biotech Values

[BTH]

Yes.

My question is what do you like about ARRY

[mcbio]

re: ECYT & ARRY

I picked some shares of each today @ $5.50 and $3.13, respectively. Any comments?

You know my thoughts on both of these. On ECYT, it looks cheap on the surface, but if folate receptor targeting is a flawed approach (and it could be given their results to date), then the bulk of their pipeline may already be flawed. On ARRY, most seem to view the MEKs as the key value-drivers I think and I still disagree with those that say NVS potentially returning MEK162 is a big value driver for them. We criticize most small-caps who tout they have regained worldwide rights from a big pharma partner who dropped their drug as if it's a positive event. I really don't see how this is any different if this is how it plays out. NVS has chosen a competitor's MEK; if ARRY's drug was the better MEK, I don't see why they would do this.